SGStacy M. Goins

Stacy M. Goins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stacy M. Goins has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hyperpolarized 129Xe MRI and spectroscopy of gas exchange abnormalities in chronic hypersensitivity pneumonitis

    by Madison Kocher Wulfeck, David G. Mummy, Shuo Zhang, Diana Kadi, Stacy Goins, Aparna Swaminathan, Robert M. Tighe, Bastiaan Driehuys, Joseph G. Mammarappallil


  • Educational Strategies in Pediatric Trauma Resuscitation Across Disciplines: A Scoping Review

    by Stacy M. Goins, Steven Thornton, Elizabeth Horne, Brooke Hoehn, Erin Brush, Julie Thamby, Angela Hemesath, Sarah Cantrell, Emily Greenwald, Elisabeth Tracy


  • Simple versus radical cholecystectomy and survival for pathologic stage T1B gallbladder cancer

    by Kristen E. Rhodin, Stacy Goins, Ryan Kramer, Austin M. Eckhoff, Garth Herbert, Kevin N. Shah, Peter J. Allen, Daniel P. Nussbaum, Dan G. Blazer, Sabino Zani, et al.


  • Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis

    by Stacy M. Goins, Hanyu Jiang, Christian B. van der Pol, Jean-Paul Salameh, Eric Lam, Robert G. Adamo, Matthew D. F. McInnes, Andreu F. Costa, An Tang, Ayman S. Alhasan, et al.

    Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.


  • Open Access

    Comparative Performance of 2018 LI‐RADS versus Modified LIRADS (mLI‐RADS): An Individual Participant Data Meta‐Analysis

    by Stacy M. Goins, Hanyu Jiang, Christian B. van der Pol, Jean‐Paul Salameh, Eric Lam, Robert G. Adamo, Matthew D.F. McInnes, Andreu F. Costa, Christopher Clarke, Sang Hyun Choi, et al.

    Background: LI‐RADS version 2018 (v2018) is used for non‐invasive diagnosis of hepatocellular carcinoma (HCC). A recently proposed modification (known as mLI‐RADS) demonstrated improved sensitivity while maintaining specificity and positive predictive value (PPV) of LI‐RADS category 5 (definite HCC) for HCC. However, mLI‐RADS requires multicenter validation.Purpose: To evaluate the performance of v2018 and mLI‐RADS for liver lesions in a large, heterogeneous, multi‐national cohort of patients at risk for HCC.Study Type: Systematic review and meta‐analysis using individual participant data (IPD) [Study Protocol: https://osf.io/duys4].Population: 2223 observations from 1817 patients (includes all LI‐RADS categories; females = 448, males = 1361, not reported = 8) at elevated risk for developing HCC (based on LI‐RADS population criteria) from 12 retrospective studies.Field Strength/Sequence: 1.5T and 3T; complete liver MRI with gadoxetate disodium, including axial T2w images and dynamic axial fat‐suppressed T1w images precontrast and in the arterial, portal venous, transitional, and hepatobiliary phases. Diffusion‐weighted imaging was used when available.Assessment: Liver observations were categorized using v2018 and mLI‐RADS. The diagnostic performance of each system's category 5 (LR‐5 and mLR‐5) for HCC were compared.Statistical Tests: The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS‐2 was applied to determine risk of bias and applicability. Diagnostic performances were assessed using the likelihood ratio test for sensitivity and specificity and the Wald test for PPV. The significance level was P < 0.05.Results: 17% (2/12) of the studies were considered low risk of bias (244 liver observations; 164 patients). When compared to v2018, mLR‐5 demonstrated higher sensitivity (61.3% vs. 46.5%, P < 0.001), similar PPV (85.3% vs. 86.3%, P = 0.89), and similar specificity (85.8% vs. 90.8%, P = 0.16) for HCC.Data Conclusion: This study confirms mLR‐5 has higher sensitivity than LR‐5 for HCC identification, while maintaining similar PPV and specificity, validating the mLI‐RADS proposal in a heterogeneous, international cohort.Level of Evidence: 3Technical Efficacy: Stage 2


  • Endovascular treatment of chronic mesenteric ischaemia secondary to a superior mesenteric artery pseudoaneurysm: a modified neurointerventional technique

    by Joseph Buchholz, Stacy Goins, Jonathan Martin

    A man in his late 60s presented with intermittent abdominal pain, nausea, vomiting and approximately 40 pounds of weight loss over the course of a year, most concerning for chronic mesenteric ischaemia. Given a prior negative workup, a CT angiogram was performed and revealed a wide neck mid-superior mesenteric artery pseudoaneurysm (PSA). As PSAs are susceptible to thrombus formation and distal emboli, this incidental finding was considered a possible explanation for his intermittent symptoms and thus required treatment. Anatomical constraints precluded traditional coiling or covered stent placement, so the interventional radiology team used a neurointerventional technique and performed a successful balloon-assisted coil embolisation of the PSA with subsequent resolution of the patient’s symptoms. More than 3 years postprocedure, the patient remains asymptomatic with no complications.

  • Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018

    by Stacy M. Goins, Robert G. Adamo, Eric Lam, Andreu F. Costa, Christian B. van der Pol, Jean-Paul Salameh, Haben Dawit, Matthew D. F. McInnes, Mustafa R. Bashir